5-MeO-DMT, scientifically known as 5-methoxy-N,N-dimethyltryptamine, and informally referred to as O-methyl-bufotenin, belongs to the tryptamine class of psychedelics. It’s widely distributed in various plant species and is notably secreted by the glands of specific toad species, such as the Colorado River toad. This compound, along with its close counterparts DMT and bufotenin (5-HO-DMT), has been employed as an entheogen in South America, where it holds spiritual and shamanic significance.

Informal terms used to describe 5-MeO-DMT include Five-methoxy, the power, bufo, and toad venom.

IUPAC name
CAS Number1019-45-0 
PubChem CID1832
CompTox Dashboard (EPA)DTXSID70144324
ECHA InfoCard100.012.558
Chemical and physical data
Molar mass218.300 g·mol−1


The synthesis of 5-MeO-DMT dates back to 1936. In 1959, it was identified as one of the psychoactive compounds present in Anadenanthera peregrina seeds, which were traditionally used to create Yopo snuff. Initially, it was thought to be a primary contributor to the snuff’s psychoactive effects. However, recent research suggests otherwise, as the seeds contain only trace amounts or sometimes none of this compound. Instead, the psychoactive properties of the snuff are attributed to bufotenin, which is the O-demethylated metabolite of 5-MeO-DMT.
The metabolism of 5-MeO-DMT primarily involves the enzyme CYP2D6.


The duration of the 5-MeO-DMT experience can vary based on the method of administration. When smoked, the effects typically last around 10 minutes, while insufflation (snorting) can extend the experience for up to 2 hours. The effects are diverse and can include profound shifts in perspective, the perception of new insights, feelings of euphoria, immersive experiences, dissociation leading to non-responsiveness, sensual and erotic enhancement, as well as occasional experiences of dysphoria, fear, terror, and panic.


5-MeO-DMT exhibits anti-anxiety and anti-depressant effects.

Religious use: The Church of the Tree of Life, which was initially founded in California in 1971 by John Mann, though now defunct, declared the sacramental use of 5-MeO-DMT. During approximately 1971 to the late 1980s, 5-MeO-DMT was discreetly available to its members.Between 1970 and 1990, smoking 5-MeO-DMT on parsley was one of the most prevalent methods of ingestion in the United States.


5-MeO-DMT, a methoxylated derivative of DMT, distinguishes itself from typical psychedelics. While many common psychedelics are believed to primarily induce psychological effects by activating serotonin 5-HT2A receptors, 5-MeO-DMT demonstrates an extraordinary 1000-fold greater affinity for 5-HT1A receptors than for 5-HT2A receptors, reflecting this preference for 5-HT1A receptors, 5-MeO-DMT profoundly suppresses the activity of dorsal raphe 5-HT neurons. Moreover, a study in rats found that its effects were diminished when a 5-HT1A selective antagonist (WAY-100635) was administered, while a 5-HT2A selective antagonist (volinanserin) didn’t bring about any significant change. Additional mechanisms of action, such as monoamine reuptake inhibition, might also play a role.
In a 2019 European study involving 42 volunteers, a single inhalation of 5-MeO-DMT resulted in a sustained improvement in life satisfaction, along with a reduction in anxiety, depression, and symptoms of post-traumatic stress disorder (PTSD). Another study conducted in 2018 showed that a single dose of 5-MeO-DMT promoted neurogenesis in mice.

Clinical Development

5-MeO-DMT is currently undergoing development and assessment for potential therapeutic applications in patients dealing with Treatment-Resistant Depression (TRD). The biopharmaceutical company GH Research has taken the initiative by sponsoring a phase 1 study conducted on healthy volunteers and a phase 1/2 study involving TRD patients. Remarkably, in the phase 2 portion of the study, 87.5% of TRD patients experienced remission on day 7. GH Research is now in the process of planning a phase 2b study for TRD patients, and they have received approval for further investigations involving patients with bipolar II disorder experiencing a current depressive episode and patients with postpartum depression.
In collaboration with King’s College London, Beckley Psytech is conducting a phase 1 study to examine the safety and tolerability of intranasal 5-MeO-DMT in healthy subjects. Beckley Psytech’s CEO, Cosmo Feilding-Mellen, highlights the potential of 5-MeO-DMT’s short-acting nature in comparison to psilocybin. He notes that the extended presence of a therapist during an MDMA or psilocybin experience, often encompassing an entire working day, may be resource-intensive and costly. Given the current global shortage of psychotherapists, this could potentially hinder patient access to treatment in the future.

Legal status


5-MeO-DMT was classified as a controlled substance in China as of October 2015.


Due to its structural similarity to N,N-dimethyltryptamine (DMT), 5-MeO-DMT is listed as a Schedule 9 prohibited substance under the Poisons Standard in Australia.


In October 2004, the health ministry, Sveriges Grodminister, categorized 5-MeO-DMT, denoted as 5-metoxi-N,N-dimetyltryptamin (5-MeO-DMT) in their regulation SFS 2004:696, as a “health hazard” under the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor), making it illegal to sell or possess in Sweden.


Since 2001, 5-MeO-DMT has been listed as a controlled substance, Attachment I BtMG (Betäubungsmittelgesetz), in Germany.


Control measures for 5-MeO-DMT were established in Turkey in December 2013.

United States

In January 2011, 5-MeO-DMT was designated as a Schedule I controlled substance in the United States.


  • What is 5-MeO-DMT?
  • 5-MeO-DMT, or 5-Methoxy-N, N-dimethyltryptamine, is a powerful psychedelic compound belonging to the tryptamine class. It’s closely related to DMT (Dimethyltryptamine) and is known for its profound and intense psychoactive effects.
  • How is 5-MeO-DMT typically consumed?
  • 5-MeO-DMT is often inhaled or smoked. It can also be consumed through vaporization or insufflation (snorting).
  • What are the effects of 5-MeO-DMT?
  • The effects of 5-MeO-DMT can vary from intense euphoria, mystical experiences, and radical shifts in perception to feelings of fear, anxiety, and even panic. Users often report experiencing a sense of unity with the universe during the peak of the experience.
  • Is 5-MeO-DMT safe to use?
  • While 5-MeO-DMT has been used for centuries in traditional rituals, its use can be risky, especially at higher doses. Excessive use may lead to nausea, vomiting, anxiety, and even extreme fear or panic. It is important to use this substance with caution and in a safe environment.
  • Is 5-MeO-DMT legal?
  • The legal status of 5-MeO-DMT varies by country and region. It is illegal in many countries, including the United States. Before considering its use, it’s crucial to research and understand the legal status in your area.
  • Can 5-MeO-DMT be used for therapeutic purposes?
  • Some ongoing research suggests potential therapeutic applications for 5-MeO-DMT, particularly in the treatment of conditions like depression, anxiety, and PTSD. Clinical trials are underway to explore these possibilities.
  • Is there a difference between 5-MeO-DMT and DMT?
  • While both are tryptamine compounds, 5-MeO-DMT and DMT have distinct effects. 5-MeO-DMT is often reported to induce a more intense and shorter-lasting experience compared to DMT.
  • What precautions should I take if I plan to use 5-MeO-DMT?
  • If you’re considering using 5-MeO-DMT, it’s important to be well-informed and take safety precautions. Ensure you’re in a safe and comfortable environment, preferably with a trusted and sober sitter. Always start with a low dose to assess your tolerance and response to the substance.
  • Are there any risks associated with using 5-MeO-DMT?
  • Yes, using 5-MeO-DMT carries potential risks, including psychological distress, physical discomfort, and the risk of accidents. People with a history of mental health issues or heart conditions should be especially cautious.
  • Is 5-MeO-DMT addictive?
  • There is limited evidence to suggest that 5-MeO-DMT is addictive in the traditional sense. However, like many psychedelics, it can be habit-forming if used irresponsibly or excessively. It’s essential to use it with care and moderation.


  1. Anvisa (2023-07-24). “RDC Nº 804 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial” [Collegiate Board Resolution No. 804 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
  2. Araújo AM, Carvalho F, Bastos M, Guedes de Pinho P, Carvalho M (August 2015). “The hallucinogenic world of tryptamines: an updated review”. Archives of Toxicology. 89 (8): 1151–1173. doi:10.1007/s00204-015-1513-x. PMID 25877327. S2CID 4825078.
  3. “Ultimate Guide to 5-MeO-DMT – Experience, Benefits, & Side Effects”. 29 June 2020.
  4. Ott J (July–September 2001). “Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine”. Journal of Psychoactive Drugs. 33 (3): 273–281. doi:10.1080/02791072.2001.10400574. PMID 11718320. S2CID 5877023.
  5. Shen HW, Jiang XL, Winter JC, Yu AM (October 2010). “Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions”. Current Drug Metabolism. 11 (8): 659–666. doi:10.2174/138920010794233495. PMC 3028383. PMID 20942780.
  6. “5-MeO-DMT Effects by Erowid”. Erowid.org. Retrieved 2021-07-30.
  7. Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR (March 2019). “5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety”. The American Journal of Drug and Alcohol Abuse. 45 (2): 161–169. doi:10.1080/00952990.2018.1545024. PMC 6430661. PMID 30822141.
  8. Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E (July 2018). “The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption”. Journal of Psychopharmacology. 32 (7): 779–792. doi:10.1177/0269881118769063. PMC 6248886. PMID 29708042.
  9. John Mann; Adam Gottlieb (2015) [First published 1970]. “back cover”. The Book of Sacraments: Ritual Use of Magical Plants. Ronin Publishing. ISBN 978-1-57951-210-1.
  10. “5-MeO-DMT Timeline”. Erowid.
  11. Ray TS (February 2010). “Psychedelics and the human receptorome”. PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO…5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
  12. Rogawski MA, Aghajanian GK (October 1981). “Serotonin autoreceptors on dorsal raphe neurons: structure-activity relationships of tryptamine analogs”. J Neurosci. 1 (10): 1148–1154. doi:10.1523/JNEUROSCI.01-10-01148.1981. PMC 6564212. PMID 6793698.
  13. Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA (December 2006). “The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats”. Psychopharmacology. 189 (3): 319–329. doi:10.1007/s00213-006-0566-1. PMID 17013638. S2CID 23396616.
  14. Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). “The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain”. European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
  15. Uthaug MV, Lancelotta R, van Oorsouw K, Kuypers KP, Mason N, Rak J, et al. (September 2019). “A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms”. Psychopharmacology. 236 (9): 2653–2666. doi:10.1007/s00213-019-05236-w. PMC 6695371. PMID 30982127.
  16. Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN (2018). “A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus”. Frontiers in Molecular Neuroscience. 11: 312. doi:10.3389/fnmol.2018.00312. PMC 6131656. PMID 30233313.
  17. “Home | GH Research”. GH Research Limited.
  18. Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG (2021). “A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers”. Frontiers in Pharmacology. 12: 760671. doi:10.3389/fphar.2021.760671. PMC 8667866. PMID 34912222.
  19. GH Research PLC (2021-12-06). “GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression”. GlobeNewswire News Room. Retrieved 2022-10-07.
  20. GH Research PLC (2022-08-23). “GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates”. GlobeNewswire News Room. Retrieved 2022-10-07.
  21. Carpenter DE (2022-02-16). “More Companies Embrace 5-MeO-DMT to Create Therapies”. Lucid News. Retrieved 2022-03-06.
  22. Siebert A. “Could 5-MeO-DMT Allow For More Affordable Psychedelic-Assisted Therapy? Beckley Psytech Thinks So”. Forbes. Retrieved 2022-03-06.
  23. Sherwood AM, Claveau R, Lancelotta R, Kaylo KW, Lenoch K (December 2020). “Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use”. ACS Omega. 5 (49): 32067–32075. doi:10.1021/acsomega.0c05099. PMC 7745443. PMID 33344861.
  24. Carpenter DE (2021-02-02). “Psychedelic Toads Pushed To The Limit, Conservationists Urge Synthetic 5-MeO-DMT Option”. Forbes. Retrieved 2021-02-04.
  25. Uthaug MV, Lancelotta R, Szabo A, Davis AK, Riba J, Ramaekers JG (March 2020). “Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment”. Psychopharmacology. 237 (3): 773–785. doi:10.1007/s00213-019-05414-w. PMC 7036074. PMID 31822925.
  26. “tryptamines: fungi”. bluezoo.org.
  27. “Erowid Psychoactive Vaults: Tryptamine FAQ”. www.erowid.org.
  28. “Some simple tryptomines” (PDF). troutsnotes.com. Retrieved 2020-07-04.
  29. Khan JI, Kennedy TJ, Christian JR DR (2011). Basic Principles of Forensic Chemistry. Springer Science & Business Media. p. 195. ISBN 978-1-934115-06-0.
  30. Carpenter DE (2022-03-06). “5-MeO-DMT: The 20-Minute Psychoactive Toad Experience That’s Transforming Lives”. Forbes.
  31. “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  32. “Poisons Standard July 2016”. Federal Register of Legislation.
  33. “Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor” (PDF). Svensk författningssamling (in Swedish). 7 September 2004.
  34. “Turkish Law” (PDF). Resmi Gazete. 16 December 2013.
  35. Drug Enforcement Administration (DEA), Department of Justice (December 2010). “Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule” (PDF). Federal Register.

Leave a Comment

Your email address will not be published. Required fields are marked *